William Blair Issues Pessimistic Forecast for RARE Earnings

Key Points

• William Blair has lowered its Q4 2026 earnings per share estimate for Ultragenyx Pharmaceutical from $0.99 to $0.94, while maintaining an "Outperform" rating and $65.00 price target for the stock.
• Ultragenyx reported a Q2 earnings per share of ($1.17), exceeding the consensus estimate of ($1.27) and showing a year-over-year revenue increase of 13.2% to $166.50 million.
• Recent analyst activity shows mixed ratings, with one analyst rating the stock as "hold" and eleven as "buy," contributing to an average rating of "Moderate Buy" with a consensus target price of $82.17.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at William Blair lowered their Q4 2026 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Tuesday, August 5th. William Blair analyst S. Corwin now anticipates that the biopharmaceutical company will earn $0.94 per share for the quarter, down from their previous estimate of $0.99. William Blair has a "Outperform" rating and a $65.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share.

Several other equities analysts have also recently issued reports on RARE. Guggenheim reiterated a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Wells Fargo & Company lowered their price objective on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. HC Wainwright raised Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective on the stock in a report on Monday, July 28th. Canaccord Genuity Group lowered their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a report on Friday. Finally, Wedbush cut their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock traded down $0.43 during trading hours on Thursday, reaching $27.12. The company had a trading volume of 571,879 shares, compared to its average volume of 1,287,806. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37. The stock's fifty day simple moving average is $33.32 and its 200 day simple moving average is $36.68. The company has a market capitalization of $2.61 billion, a P/E ratio of -4.91 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. The firm had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The company's revenue for the quarter was up 13.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.52) earnings per share.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $35,000. Invesco Ltd. increased its stake in Ultragenyx Pharmaceutical by 1.5% in the 4th quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock worth $71,509,000 after purchasing an additional 25,487 shares in the last quarter. Renaissance Technologies LLC increased its stake in Ultragenyx Pharmaceutical by 39.9% in the 4th quarter. Renaissance Technologies LLC now owns 254,700 shares of the biopharmaceutical company's stock worth $10,715,000 after purchasing an additional 72,600 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $916,000. Finally, F M Investments LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at about $1,767,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director owned 15,344 shares of the company's stock, valued at approximately $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is currently owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.